Table 3.
Distribution of patients with shortened treatment according to DAA regimen.
| DAA regimen | N | No. of patients in whom treatment duration shortened | % of total study patients in whom treatment duration shortened (%) | % of patients in whom treatment duration shortened per DAA regimen (%) | DAA-time saved (%) |
|---|---|---|---|---|---|
| SOF/VEL | 11 | 5 | 46 | 46 | 17 |
| SOF/LED | 6 | 2 | 18 | 33 | 11 |
| ELB/GRZ | 8 | 4 | 36 | 50 | 17 |
| GLE/PIB | 4 | 0 | 0 | 0 | |
| Total | 29 | 11 | 100 | N/A | 14 |
SOF/VEL, sofosbuvir/velpatasvir; SOF/LED, sofosbuvir/ledipasvir; ELB/GRZ, elbasvir/grazoprevir; GLE/PIB, glecaprevir/pibrentasvir.